乌帕替尼抑制类风湿关节炎结构性关节损伤进展:SELECT 3期项目1年结果
在两项3期随机对照试验中评估乌帕替尼单药或联合甲氨蝶呤(MTX)对类风湿关节炎(RA)患者48周内结构性关节损伤进展的抑制作用。SELECT-EARLY 纳入945例未使用过MTX的患者,SELECT-COMPARE 纳入1629例MTX应答不足者。乌帕替尼单药或联合背景MTX在48周内有效抑制了结构性关节损伤进展。
要点
- SELECT-EARLY:48周mTSS平均变化乌帕替尼15mg为0.03、30mg为0.14、MTX为1.00(两种剂量vs MTX均P<0.001)。
- SELECT-COMPARE:乌帕替尼15mg联合MTX组mTSS平均变化0.28 vs 安慰剂联合MTX组1.73(P<0.001)。
- 阿达木单抗联合MTX组mTSS平均变化为0.39。
核心结论
- 乌帕替尼单药或联合背景MTX可在48周内有效抑制未使用过MTX及MTX应答不足的RA患者的结构性关节损伤进展。
研究设计与样本
- 两项3期随机对照试验:SELECT-EARLY(n=945)将未使用过MTX的患者随机分配至乌帕替尼15mg或30mg每日一次或MTX单药治疗。
- SELECT-COMPARE(n=1629)将MTX应答不足者随机分配至乌帕替尼15mg每日一次或阿达木单抗40mg隔周一次或安慰剂,均联合背景MTX。
- 通过线性外推法处理缺失数据及治疗转换,并进行观察数据分析,评估改良总Sharp评分(mTSS)、关节间隙狭窄及侵蚀评分较基线的平均变化。
主要发现
- SELECT-EARLY中,基于线性外推法,从基线至第48周mTSS平均变化:乌帕替尼15mg组0.03、乌帕替尼30mg组0.14、MTX组1.00(两种乌帕替尼剂量vs MTX均P<0.001)。
- SELECT-COMPARE中,乌帕替尼15mg联合MTX组从基线至第48周mTSS平均变化为0.28,安慰剂联合MTX组为1.73(P<0.001)。
- SELECT-COMPARE中,阿达木单抗联合MTX组从基线至第48周mTSS平均变化为0.39。
关键数值与推荐
- SELECT-EARLY:mTSS平均变化乌帕替尼15mg组0.03 vs MTX组1.00(P<0.001);乌帕替尼30mg组0.14 vs MTX组1.00(P<0.001)。
- SELECT-COMPARE:mTSS平均变化乌帕替尼15mg联合MTX组0.28 vs 安慰剂联合MTX组1.73(P<0.001)。
- SELECT-COMPARE:阿达木单抗联合MTX组mTSS平均变化为0.39。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the inhibition of progression of structural joint damage through week 48 in patients with moderately to severely active RA receiving upadacitinib as monotherapy or in combination with MTX. METHODS: Radiographic progression was assessed in two phase 3 randomized controlled trials. MTX-naïve patients were randomized to upadacitinib 15 or 30 mg once daily or MTX monotherapy (SELECT-EARLY, n = 945), while MTX inadequate responders (IRs) were randomized to upadacitinib 15 mg once daily or adalimumab 40 mg every other week or placebo added to background MTX (SELECT-COMPARE, n = 1629). The mean changes from baseline in modified total Sharp score (mTSS), joint space narrowing and erosion scores were determined. Data were analysed both by linear extrapolation for missing data imputation and treatment switching and as observed. RESULTS: In patients naïve or with limited exposure to MTX (SELECT-EARLY), mean changes from baseline to week 48 in mTSS were 0.03 for upadacitinib 15 mg, 0.14 for upadacitinib 30 mg and 1.00 for MTX based on linear extrapolation (P < 0.001 for both upadacitinib doses vs MTX). Among patients with an inadequate response to MTX (SELECT-COMPARE), the mean change from baseline in mTSS was significantly reduced in the upadacitinib 15 mg plus MTX group vs placebo plus MTX (0.28 vs 1.73; P < 0.001). The mean change from baseline in the adalimumab plus MTX group was 0.39. CONCLUSION: Upadacitinib monotherapy or in combination with background MTX was effective in inhibiting the progression of structural joint damage through week 48 in MTX-naïve and MTX-IR patients with RA. TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT02706873 and NCT02629159.
引用
- Peterfy CG, Strand V, Friedman A, et al. Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program. Rheumatology (Oxford). 2022. PMID: 34897366. doi:10.1093/rheumatology/keab861
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。